Добірка наукової літератури з теми "Carcinoma Endometrio"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Carcinoma Endometrio".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Carcinoma Endometrio"
Morán Mejía, Javier Alberto, Rosario Velásquez, Victor Argueta, and Roberto Orozco. "Carcinoma endometriode sincrónico que afecta útero y trompa uterina." Revista médica (Colegio de Médicos y Cirujanos de Guatemala) 159, no. 1 (June 22, 2020): 41–43. http://dx.doi.org/10.36109/rmg.v159i1.173.
Повний текст джерелаCruz Muñóz, Héctor. "Sobre el diagnóstico, pronóstico y tratamiento del carcinoma endometrial." Revista Peruana de Ginecología y Obstetricia 12, no. 3 (June 12, 2015): 324–72. http://dx.doi.org/10.31403/rpgo.v12i884.
Повний текст джерелаAqueche, Gabriela, and Marisol Gramajo. "Carcinoma de células escamosas primario de endometrio." Revista médica (Colegio de Médicos y Cirujanos de Guatemala) 160, no. 3 (December 6, 2021): 298–300. http://dx.doi.org/10.36109/rmg.v160i3.382.
Повний текст джерелаDíaz, Juan, Marco Martell, Jorge Pomatanta, Luz Cisneros, Guillermo Fonseca, and Rafael Roeder. "Carcinoma de endometrio: cuadro clínico-patológico." Revista Peruana de Ginecología y Obstetricia 43, no. 3 (June 25, 2015): 202–8. http://dx.doi.org/10.31403/rpgo.v43i1072.
Повний текст джерелаWood, Juan, Alfredo Durán, Sergio Fuensalida, and Alberto Guzmán. "Relación entre la hiperplasia endometrial y el adenocarcinoma del endometrio." Revista Peruana de Ginecología y Obstetricia 1, no. 2 (June 12, 2015): 1–13. http://dx.doi.org/10.31403/rpgo.v1i896.
Повний текст джерелаAguilar, Ceny. "Carcinoma de Endometrio de Casos." Anales de la Facultad de Medicina 56, no. 1 (April 7, 2014): 17. http://dx.doi.org/10.15381/anales.v56i1.4918.
Повний текст джерелаElmore, Lynne W., Kelly Domson, Jonathan R. Moore, Michael Kornstein, and R. Tucker Burks. "Expression of c-Kit (CD117) in Benign and Malignant Human Endometrial Epithelium." Archives of Pathology & Laboratory Medicine 125, no. 1 (January 1, 2001): 146–51. http://dx.doi.org/10.5858/2001-125-0146-eockci.
Повний текст джерелаPérez Montiel, Camilo, María Murillo Salas, César Redondo Bermúdez, and Katherine Redondo de Oro. "Endometritis xantogranulomatosa asociada a carcinoma escamocelular de cérvix: presentación de un caso y revisión de la literatura." Revista Ciencias Biomédicas 8, no. 2 (November 7, 2020): 105–10. http://dx.doi.org/10.32997/rcb-2019-2877.
Повний текст джерелаPérez-Montiel, Camilo Andrés. "Nueva clasificación molecular del carcinoma de endometrio: impacto en el diagnóstico histopatológico, tratamiento y pronóstico." MedUNAB 24, no. 3 (January 5, 2022): 365–74. http://dx.doi.org/10.29375/01237047.4015.
Повний текст джерелаFerrero, S., C. Esteve, I. Mora, J. Sabrià, E. González, and J. M. Lailla. "Carcinoma de endometrio y ovario sincrónicos." Clínica e Investigación en Ginecología y Obstetricia 34, no. 2 (April 2007): 77–79. http://dx.doi.org/10.1016/s0210-573x(07)74478-7.
Повний текст джерелаДисертації з теми "Carcinoma Endometrio"
Velasco, Sánchez Ana. "Oncogenes y genes supresores de tumores en carcinoma de endometrio." Doctoral thesis, Universitat de Lleida, 2012. http://hdl.handle.net/10803/110545.
Повний текст джерелаL'objectiu principal d'aquest treball ha estat la identificació d'alteracions moleculars que participin de manera significativa al desenvolupament i la progressió del càncer d'endometri, amb el propòsit d'afegir més claus pel descobriment de noves dianes de diagnosi i teràpies individuals contra aquesta patologia. El treball ha estat centrat en l’estudi de modificacions en l’ADN de les cèl-lules que formen el teixit tumoral en una sèrie de pacients amb carcinoma endometrial, en concret, en l’anàlisi mutacional del gens PIK3CA i FGFR2 i l’anàlisi de hipermetilació del promotor dels gens RASSF1A i SPRY2, elements que formen part d’importants vies de transducció de senyals implicades principalment en processos de creixement i diferenciació cel-lular. En primer lloc hem advertit cert grau de variabilitat en el patró d'expressió dels gens estudiats entre els teixits tumoral i no tumoral i aquestes diferències d'expressió són, en part, degudes a l'existència de hipermetilació en les regions promotores dels gens implicats. Així mateix, la presencia de mutacions en regions gèniques que codifiquen parts de la proteïna claus per la seva funció a la cèl-lula, és també un factor que modifica el patró d'expressió entre entre els teixits tumoral i no tumoral. En concret, després de l’anàlisi immunohistoquímic de l’expressió de RASSF1A i la presència o absència de metilació a la zona promotora del gen RASSF1A, es van detectar tumors amb nivells d’expressió reduïts i presència de hipermetilació en el promotor, ambdós fenòmens associats de manera estadísticament significativa. El mateix passa, encara que amb diferent grau, amb l’expressió de SPRY2 en alguns tumors en associació amb la presència de ipermetilació en el promotor del gen. A través d’aquest anàlisi hem descobert que l’expressió de SPRY2 presenta variabilitat en les glàndules endometrials dels teixits no tumorals al llarg del cicle menstrual. D'altra banda hem vist com el gen PIK3CA es troba freqüentment mutat en les cèl-lules que formen els tumors de carcinoma d'endometri i coincideix amb la presència de mutacions en el gen PTEN. No obstant això, la freqüència de mutacions en el gen FGFR2 s'ha mostrat baixa encara que la seva expressió a nivell inmunohistoquímic reflecteix diferencies entre carcinoma de tipus endometrioide y no endometrioide. Finalment, afegir una revisió d'un dels fenòmens més freqüent en la formació i el progrés dels tumors en carcinoma d'endometri: el concepte de "pèrdua de heterozigositat". En aquest treball hem considerat primordial incloure una obra en que es realitza una incursió als mecanismes moleculars a través dels quals es produeix la pèrdua de heterozigositat, aixi com els mètodes que s'utilitzen en la seva detecció i el significant d'alguns patrons de pèrdua de heterozigositat en determinades regions cromosòmiques en carcinoma d'endometri.
The main point of this study was the identification of molecular alterations that participate in the development and progression of endometrial cancer, in order to add more keys to the discovery of new targets for diagnosis and therapies against this disease. The work has been focused on the study of molecular alterations of DNA from tumour tissues in a series of endometrial carcinoma patients, above all, mutational analysis of PIK3CA and FGFR2 genes and analysis of promoter hyper methylation of SPRY2 and RASSF2A genes, together forming part of signal transduction pathways that are involved in processes of growth and cell differentiation. To begin with, we noticed some variability in the gene expression pattern examined between tumour and normal tissue, and these differences are partly due to hyper methylation in promoter regions at the involved genes. Likewise, mutations in gene regions encoding key protein domains in the cell are also a factor that modifies the gene expression pattern between tumour and normal tissue. In particular, after analysing the immunohistochemical expression of RASSF1A and the presence or absence of methylation in the RASSF1A gene promoter we detected tumours with low expression levels and promoter hyper methylation. The same applies, albeit in a different degree, with SPRY2 expression in some tumours in association with the presence of gene promoter hyper methylation. Through this analysis we found some SPRY2 expression variability in endometrial glands from non-tumour tissues throughout the menstrual cycle. On the other hand we have seen that the PIK3CA gene is frequently mutated in tumour cells from endometrial carcinoma, and this is also a PTEN gene mutation coincident event. However, FGFR2 gene mutation ratio has shown to be low although immunohistochemical expression reflects differences between endometrioid endometrial carcinoma and no-endometrioid type. Finally, we wanted to add a review of one of the phenomena, which occurs more frequently during the formation and progress of tumours in endometrial carcinoma: LOH "loss of heterozygosity". We have considered essential include a review work about the molecular mechanisms through which loss of heterozygosity is produced, the methods used in their detection and significance of some patterns of loss of heterozygosity in specific chromosomal regions in endometrial carcinoma.
Tonon, Ângela Favorito Santarém [UNESP]. "Claudina-3 e Claudina- 4, potenciais marcadores de agressividade no carcinoma endometrial Tipo I." Universidade Estadual Paulista (UNESP), 2013. http://hdl.handle.net/11449/108608.
Повний текст джерелаO Carcinoma de Endométrio é a neoplasia epitelial maligna que acomete mulheres no pré, pós e peri -menopausa. Segundo diferenças endócrinas, metabólicas, fatores de risco e morfologia é classificado em dois grandes grupos: Tipo I (endometrióide) e Tipo II (não endometrióide). O Tipo I perfaz 90 % dos carcinomas de endométrio e sua patogenia esta ligada a exposição excessiva ao estrógeno. O Tipo II é incomum, com fatores predisponentes menos conhecidos. O sintoma mais relevante do carcinoma de endométrio é o sangramento pós-menopausa. Seu diagnóstico é feito pela comprovação histológica, associada aos exames de imagem e laboratoriais. Seu tratamento é fundamentalmente cirúrgico. O fator prognóstico mais importante é a presença ou ausência de metástase nos linfonodos regionais. Atualmente, buscam-se marcadores biológicos e teciduais que indiquem pior prognóstico. Este trabalho verificou a imunoexpressão da claudina-3 (CLDN3) e claudina-4 (CLDN4) nos carcinomas de endométrio Tipo I e Tipo II, relacionando-as com endométrio proliferativo e atrófico, aspectos clínicos, anatomopatológicos, perfil hormonal, índice de proliferação celular e expressão da p53, na tentativa de estabelecer a importância destas proteínas na progressão e agressividade tumoral e o seu valor prognóstico. Foram estudados 79 casos de carcinoma de endométrio e comparados com 74 endométrios normais. Avaliou-se a imunoexpressão das CLDNs 3 e 4, receptor estrogênico, receptor de progesterona, índice de proliferação celular (Ki67) e p53, pela técnica de imunoistoquímica. Observou-se que o padrão de coloração da membrana para CLDN3 se mostrou difuso nos carcinomas, quando comparado com os endométrios normais que exibiu padrão focal. O número de células marcadas com CLDN3 estava diminuído nos carcinomas Tipo I, porém com intensidade aumentada. Nesta análise foi possível verificar que ...
Carcinoma of the Endometrium is a malignant epithelial tumor which affects pre, peri and post-menopausal women. It is classified into two major groups, according to endocrine, metabolic risk factors and morphological differences: Type I (endometrioid) and Type II (non-endometrioid). Type I accounts for 90% of all endometrial carcinomas and its pathogenesis is linked to excessive estrogen exposure. The Type II is less common, with poorly defined predisposing factors. The most important symptom of endometrial carcinoma is postmenopausal bleeding. Diagnosis is achieved through histological evidence, in association with imaging and laboratorial exams. Treatment is primarily surgical. The most important prognostic factor is the presence or absence of metastases in regional lymph nodes. Bio and tissue markers that indicate worse prognosis are the focus of current research. This study examined the immunoexpression of claudin-3 (CLDN3) and claudin-4 (CLDN4) in endometrial carcinomas Type I and Type II, and their relation to proliferative and atrophic endometrium, clinical and pathological features, hormonal status, proliferation index and p53 expression, in an attempt to establish the importance of these proteins in tumor progression and aggressiveness and their prognostic value. Seventy-nine cases of endometrial carcinoma were studied and compared with 74 normal endometria. The immunoexpression of CLDNs 3 and 4, estrogen receptor, progesterone receptor, cell proliferation index (Ki67) and p53 were all evaluated by immunohistochemistry. Observation verified that the pattern of membrane staining for CLDN3 was diffuse in carcinomas compared with normal endometrium which presented a focal pattern. The number of cells stained with CLDN3 was lower in Type I carcinomas, while staining intensity was greater. Analysis verified that 25% of cases with high expression of CLDN4 and Ki-67 developed metastasis, while 33% of cases with greater CLDN4 staining ...
Lombardelli, Karen Vicencia Pingarilho. "Ressonancia magnetica resumida na avaliação da extensão do carcinoma de endometrio." [s.n.], 2008. http://repositorio.unicamp.br/jspui/handle/REPOSIP/310562.
Повний текст джерелаDissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas
Made available in DSpace on 2018-08-11T20:18:21Z (GMT). No. of bitstreams: 1 Lombardelli_KarenVicenciaPingarilho_M.pdf: 1393759 bytes, checksum: 03f9bf792d32993984a7a2ab742d670a (MD5) Previous issue date: 2008
Resumo: Introdução: A ressonância magnética (RM) é um exame que pode auxiliar no estadiamento pré-cirúrgico da paciente com carcinoma de endométrio, o que permite planejar mais adequadamente a cirurgia, principalmente quando há evidências de doença avançada e em mulheres com comorbidades clínicas relevantes. Todavia, é um exame demorado, exige cooperação e imobilidade, emite ruído e o espaço físico é restrito, ocasionando desconforto e claustrofobia. Motivos referidos, inclusive como justificativa de interrupção do exame. A mobilidade durante o exame, incluindo movimentos respiratórios acentuados, assim como o alto índice de obesidade em mulheres com carcinoma de endométrio podem gerar artefatos que comprometem a qualidade da imagem, prejudicado o diagnóstico final. Simplificar o exame com redução do tempo de duração sem prejudicar a qualidade do diagnóstico seria muito útil. Objetivos: O objetivo deste estudo foi avaliar se a subtração das seqüências T1 FS sagital e T2 TSE coronal, sem contraste e com aquisições de alta resolução, comprometeria o desempenho diagnóstico na avaliação da extensão do carcinoma de endométrio. Material e Métodos: Este estudo foi observacional e descritivo, de corte transversal. Foram incluídas 62 mulheres com diagnóstico histológico de carcinoma de endométrio. As pacientes fizeram RM da pelve que foi analisada por dois médicos especialistas, sendo que um avaliou o exame completo e o outro o exame resumido, sem troca de informações entre eles. Os achados da RM completa e resumida foram comparados com os laudos anatomopatológicos. Para testar a associação entre as variáveis qualitativas foi utilizado o teste qui-quadrado. A concordância diagnóstica entre os exames completo e resumido da RM foi analisada pelo Coeficiente de Kappa. Resultados: As medianas, médias, desvios-padrão e valores máximos das medidas do maior diâmetro do tumor avaliadas pelas RMC, RMR e patologia foram muito próximas. As medianas, médias, desvios-padrão, valores mínimos e valores máximos do volume do tumor avaliado pelas RMC e RMR foram muito próximos. A mediana do volume do tumor avaliado pela patologia foi muito próxima das medianas obtidas pela ressonância magnética, enquanto que a média, desvio-padrão e valor máximo apresentaram valores maiores. Conclusões: A RMR apresenta desempenho semelhante ao da RMC na avaliação da extensão do carcinoma do endométrio. A concordâncJa observada para avaliação da invasão, miometrial, do colo do útero e dos linfonodos pélvicos foi classificada como muito boa ou excelente. A concordância na avaliação da invasão do colo do útero entre a patologia e as RMC e RMR foi classificada como muito boa (Tabela 2). A concordância observada para avaliação das invasões miometrial e do colo do útero entre os exames de RM foi classificada como muito boa ou excelente. Portanto, é possível utilizar o exame de RM sem as seqüências T1 SE sagital sem contraste e T2 TSE caronal, pois não haverá prejuízo na qualidade do diagnóstico
Abstract: Background: Magnetic resonance imaging (MRI) is an exam that may be helpful in establishing presurgical staging of patients with endometrial carcinoma, allowing a more appropriate surgical procedure to be planned, principally in the case of advanced disease or in women with relevant clinical comorbidities. However, it is a protracted exam that requires cooperation and immobility. In addition, it is noisy and physical space is restricted, often causing discomfort, anxiety and claustrophobia that may lead to interruption of the exam. Movements including accentuated breathing may generate artifacts that compromise the quality of images. Simplifying the exam by reducing the time required to carry it out without affecting the quality of diagnosis would be extremely useful. Objectives: To evaluate whether modification to the routine MRI (complete MRI) by eliminating the non contrast high resolution sagittal T1-weighted FS and caronal T2-weighted TSE sequences (resumed MRI), negatively affects performance of this exam in the diagnosis of the extent of endometrial carcinoma. Methods: A cross sectional, observational, descriptive study was carried out in 62 women with endometrial carcinoma. All underwent pelvic MRI, which was analyzed by two radiologists. Complete and rapid MRI findings were compared with anatomopathology reports. The chi-square test was used to test the association between qualitative variables. Diagnostic agreement between complete and resumed MRI was analyzed using the kappa coefficient. Results: There were no statistically significant differences in the medians, means, standard deviations or maximum values of the measurements of the greatest diameter and of tumor volume as evaluated by complete MRI, resumed MRI and pathology. With respect to myometrial invasion, agreement between complete and resumed MRI was classified as very good, with a kappa coefficient of 0.73 (0.54 - 0.93). Agreement in the evaluation of myometrial invasion between pathology and complete or resumed MRI was classified as good. With respect to cervical invasion, agreement between complete and rapid MRI was classified as excellent, with a kappa coefficient of 0.96 (0.87 - 1.00). Agreement in the evaluation of cervical invasion between pathology and complete and resumed MRI was classified as very good. With respect to pelvic Iymph nodes, agreement between complete and resumed MRI was classified as excellent, with kappa coefficients of 0.93 (0.84 - 1.00) and 0.96 (0.90 - 1.00), respectively. Conclusions: MRI without the non-contrast sagittal T1-weighted SE and coronal T2-weighted TSE sequences maintains the same performance as complete MRI in evaluating the extent of endometrial carcinoma. The shorter time required to carry out the exam would, therefore, be beneficial to the patients, reducing their discomfort and, principally, decreasing reactions of anxiety and claustrophobia. Moreover, costs to healthcare services, and indirectly to the patients, would also be reduced, since the productivity of the equipment and the team would be higher
Mestrado
Ciencias Biomedicas
Mestre em Tocoginecologia
Testoni, Blasco di Sciacca Alessandra Lucia Maria. "Metalloproteasi 9, TIMP-1 e Osteopontina quali possibili biomarcatori del carcinoma dell endometrio." Doctoral thesis, Università di Catania, 2012. http://hdl.handle.net/10761/1217.
Повний текст джерелаCubo, Abert Montserrat. "Estadificación prequirúrgica del carcinoma endometrial mediante ecografía en dos y tres dimensiones." Doctoral thesis, Universitat Autònoma de Barcelona, 2021. http://hdl.handle.net/10803/672056.
Повний текст джерелаObjetivos: Nuestro objetivo fue comparar el rendimiento diagnóstico de la ecografía transvaginal (ETV) y la resonancia magnética (RM) para predecir la profundidad de la invasión del miometrio (IMP) y la invasión del estroma cervical (IEC) en pacientes con cáncer de endometrio (CE). Métodos: Estudio prospectivo y consecutivo que incluye todas las pacientes con CE diagnosticadas entre octubre de 2013 y julio de 2018 en el Hospital Vall d’Hebron de Barcelona. La estadificación preoperatoria se realizó con ETV y RM seguida de estadificación quirúrgica. La histología final se consideró como estándar de referencia. Se calcularon la sensibilidad, la especificidad, las razones de probabilidad y la precisión diagnóstica para ambas técnicas de imagen para la predicción de IMP y IEC. Se calculó el índice de concordancia. Se utilizaron las pautas STARD 2015. Resultados: Se incluyeron un total de 177 pacientes de forma consecutiva. La sensibilidad fue mayor para ETV en comparación con RM tanto para la predicción de IMP (68% (95% CI 55-79) versus 60% (95% CI 47-72), respectivamente) como para la predicción de IEC (49% (95% CI 35- 62) versus 29% (IC 95% 18-43), respectivamente). Las especificidades fueron similares para la predicción de IMP (ETV 84% (95% CI 77-90) y ETV 92% (95% CI 85-96)) e iguales para IEC (95% (95% CI 90-98). El índice de acuerdo entre ETV y RM fue 0,74 para IMP y 0,99 para IEC. Conclusiones: El rendimiento diagnóstico de ETV no es inferior a la RM para la predicción de IMP y la IEC en el carcinoma de endometrio y puede desempeñar un papel como técnica de imagen de primera línea en la evaluación preoperatoria del cáncer de endometrio.
Objectives: We aimed to compare the diagnostic performance of transvaginal ultrasound (TVUS) and magnetic resonance imaging (MRI) to predict the depth of myometrial invasion (DMI) and cervical stromal invasion (CSI) in patients with endometrial cancer (EC). Methods: Prospective and consecutive study including all EC diagnosed between October 2013 and July 2018 at the Vall d’Hebron Hospital in Barcelona. Preoperative staging was performed with TVUS and MRI followed by surgical staging. Final histology was considered as the reference standard. Sensitivity, specificity, likelihood ratios and diagnostic accuracy were calculated for both imaging techniques for the prediction of DMI and CSI. Agreement index was calculated. The STARD 2015 guidelines were used. Results: A total of 177 patients were consecutively included. Sensitivity was higher for TVUS compared to MRI both for the prediction of DMI (68% (95%CI 55-79) versus 60% (95%CI 47-72), respectively) and CSI (49% (95%CI 35-62) versus 29% (95%CI 18-43), respectively). Specificities were similar for the prediction of DMI (TVUS 84% (95%CI 77-90) and MRI 92% (95%CI 85-96)) and equal for CSI (95% (95%CI 90-98). The agreement index between TVUS and MRI was 0.74 for DMI and 0.99 for CSI. Conclusions: The diagnostic performance of TVUS is not inferior to MRI for the prediction of DMI and CSI in EC and can play a role as a first line imaging technique in the preoperative evaluation of endometrial cancer.
Universitat Autònoma de Barcelona. Programa de Doctorat en Pediatria, Obstetrícia i Ginecologia
Sorolla, Bardají Anabel. "Estudi del proteasoma i altres dianes terapèutiques en el melanoma i el carcinoma d’endometri." Doctoral thesis, Universitat de Lleida, 2012. http://hdl.handle.net/10803/83625.
Повний текст джерелаDada la resistencia a la quimioterapia que presenta el melanoma y el carcinoma de endometrio avanzado, es importante aquella investigación destinada a buscar dianas terapéuticas. En este trabajo hemos investigado los efectos de análogos de la somatostatina (SAs), de inhibidores del proteasoma (PI) como Bortezomib, del inhibidor de receptores tirosina cinasa Sunitinib y la combinación de Sunitinib y Bortezomib en líneas celulares de melanoma. Esta combinación también la hemos testado en el carcinoma de endometrio. Se observa que las células de melanoma expresan varios receptores de la somatostatina. Los PI son eficientes a la hora de inducir una parada en el ciclo celular y apoptosis. Las líneas celulares que presentan PDGFR α i VEGFR2 son sensibles a Sunitinib, y éste interacciona con Bortezomib de forma sinérgica. En el carcinoma de endometrio, Sunitinib induce una parada en el ciclo celular, apoptosis, inhibe la via NFκB e interacciona sinérgicamente con Bortezomib. Los SAs y PI podrían ser útiles en combinación con otros agentes y el uso de Bortezomib y Sunitinib ha demostrado ser efectivo en determinados casos de melanoma y en el carcinoma de endometrio.
As advanced melanoma and endometrial carcinoma is highly resistant to chemotherapy it is important the research focused to the search of therapeutic targets. In the present work, we have investigated the effects of somatostatin analogues (SAs), proteasome inhibitors (PI) such as Bortezomib, the tyrosine kinase receptor inhibitor Sunitinib and the combined therapy of Sunitinib and Bortezomib. This combination has been also tested in endometrial carcinoma. It is observed that melanoma cell lines express various somatostatin receptors. In addition, proteasome inhibitors induce a cell cycle arrest and apoptosis. Those cells presenting activated PDGFRα or VEGFR2 are more sensitive to Sunitinib and this interacts synergistically with Bortezomib. In endometrial carcinoma, Sunitinib induces a cell cycle arrest, apoptosis, inhibits NFκB pathway and interacts synergistically with Bortezomib. The SAs and PI could be useful combined with other agents and the use of Bortezomib and Sunitinib has shown to be effective in certain cases of melanoma and in endometrial carcinoma.
Muñoz, Menéndez Ana Belén. "Resonancia magnética nuclear y marcadores moleculares en el estudio prequirúrgico de pacientes con carcinoma de endometrio. Correlación con el estadio quirúrgico final." Doctoral thesis, Universidad de Cantabria, 2014. http://hdl.handle.net/10803/133095.
Повний текст джерелаIn general , the use of preoperative magnetic imaging is accepted for staging in endometrial carcinoma. However, in our hospital, we have been observing a discrepancy between the results of preoperative MRI and subsequent surgical staging . This has made us wonder if, in our environment, it is a necessary diagnostic test in all our patients for diagnosis prior to surgery , or if , perhaps , we should exclude it from our endometrial cancer staging protocol. We studied the patients with endometrial cancer who had surgery in our department between January 2007 and December 2011, which had undergone preoperative MRI. There was a complete coincidence between the results of the Nuclear Magnetic Resonance preoperative and final surgical stage only in 47.2 % of cases analyzed. The data obtained in the subgroup of type I endometrial carcinomas are much more reasonable, seeing a 63.9 % correct staging , more in line with published studies on the topic, and in any case of this subgroup, staging failure meant a change in the final treatment or prognosis.
Dahmoun, Marju. "Apoptosis, proliferation, and sex steroid receptors in endometrium and endometrial carcinoma." Doctoral thesis, Umeå : Univ, 2003. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-112.
Повний текст джерелаVaskivuo, T. (Tommi). "Regulation of apoptosis in the female reproductive system." Doctoral thesis, University of Oulu, 2002. http://urn.fi/urn:isbn:9514266676.
Повний текст джерелаHAMID, ATIA AKHTAR. "Cyclical Change of hMSH2 Protein Expression in Normal endometrium during the Menstrual Cycle and its Overexpression in Endometrial Hyperplasia and Sporadic Endometrial Carcinoma." Kyoto University, 2002. http://hdl.handle.net/2433/149704.
Повний текст джерела0048
新制・課程博士
博士(医学)
甲第9461号
医博第2474号
新制||医||795(附属図書館)
UT51-2002-G219
京都大学大学院医学研究科外科系器官外科学(婦人科学産科学)専攻
(主査)教授 中畑 龍俊, 教授 丹羽 太貫, 教授 藤井 信吾
学位規則第4条第1項該当
Книги з теми "Carcinoma Endometrio"
Li, Shen-yi, and En-yu Wang. Endometrial Carcinoma. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74821-9.
Повний текст джерела1942-, Wang En-yu, and Seta Michihiro, eds. Endometrial carcinoma. Beijing: People's Medical Pub. House, 1990.
Знайти повний текст джерелаBeatriz, Jiménez-Ayala Portillo, ed. Endometrial adenocarcinoma: Prevention and early diagnosis. Basel: Karger, 2008.
Знайти повний текст джерелаHedrick Ellenson, Lora, ed. Molecular Genetics of Endometrial Carcinoma. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-43139-0.
Повний текст джерелаKuramoto, Hiroyuki, and Masato Nishida, eds. Cell and Molecular Biology of Endometrial Carcinoma. Tokyo: Springer Japan, 2003. http://dx.doi.org/10.1007/978-4-431-53981-0.
Повний текст джерелаSeiichiro, Fujimoto, ed. Paraaortic lymph node metastasis in gynecologic malignancies. Sapporo, Japan: Hokkaido University School of Medicine, 2000.
Знайти повний текст джерелаCook, Linda S., Angela L. W. Meisner, and Noel S. Weiss. Endometrial Cancer. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780190238667.003.0047.
Повний текст джерелаSeta, Michihiro, Shen-yi Li, and En-yu Wang. Endometrial Carcinoma. Springer London, Limited, 2012.
Знайти повний текст джерелаC, Malkin J., and Tindall V. R. 1928-, eds. Endometrial carcinoma. Duphar Medical Relations, 1988.
Знайти повний текст джерелаCarton, James. Gynaecological pathology. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198759584.003.0012.
Повний текст джерелаЧастини книг з теми "Carcinoma Endometrio"
Li, Shen-yi, and En-yu Wang. "Epidemiology and Etiology." In Endometrial Carcinoma, 1–22. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74821-9_1.
Повний текст джерелаLi, Shen-yi, and En-yu Wang. "Pathology." In Endometrial Carcinoma, 23–58. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74821-9_2.
Повний текст джерелаLi, Shen-yi, and En-yu Wang. "Diagnosis of Endometrial Carcinoma." In Endometrial Carcinoma, 59–92. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74821-9_3.
Повний текст джерелаLi, Shen-yi, and En-yu Wang. "Treatment of Endometrial Carcinoma." In Endometrial Carcinoma, 93–158. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74821-9_4.
Повний текст джерелаLi, Shen-yi, and En-yu Wang. "Prognosis of Endometrial Carcinoma." In Endometrial Carcinoma, 159–84. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74821-9_5.
Повний текст джерелаLi, Shen-yi, and En-yu Wang. "Laboratory Research." In Endometrial Carcinoma, 185–225. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74821-9_6.
Повний текст джерелаLi, Shen-yi, and En-yu Wang. "Medicopsychologic Problems in Patients with Gynecologic Cancers." In Endometrial Carcinoma, 226–41. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74821-9_7.
Повний текст джерелаMurdock, Tricia A., Emanuela F. T. Veras, Robert J. Kurman, and Michael T. Mazur. "Endometrial Carcinoma." In Diagnosis of Endometrial Biopsies and Curettings, 261–332. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-98608-1_10.
Повний текст джерелаFrei Bonel, Kathrin A., and Karen Kinkel. "Endometrial Carcinoma." In MRI and CT of the Female Pelvis, 101–19. Berlin, Heidelberg: Springer Berlin Heidelberg, 2007. http://dx.doi.org/10.1007/978-3-540-68212-7_6.
Повний текст джерелаAllen, Derek C. "Endometrial Carcinoma." In Histopathology Reporting, 229–38. London: Springer London, 2000. http://dx.doi.org/10.1007/978-1-4471-3671-2_24.
Повний текст джерелаТези доповідей конференцій з теми "Carcinoma Endometrio"
Lekhi, Anshika, Rahul Manchanda, Nidhi Jain, Sravani Chithra, and Hena Kausar. "Presentation of endometrial carcinoma in young women." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685342.
Повний текст джерелаGupta, Shaveta. "Comparison of MRI findings with actual HPE findings in case of carcinoma endometrium." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685340.
Повний текст джерелаPandher, Dilpreet K. "To find the prevalence of female genital tract malignancies in a tertiary care hospital." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685376.
Повний текст джерелаPandher, Dilpreet K. "To find the prevalence of female genital tract malignancies in a tertiary care hospital." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685349.
Повний текст джерелаYela, Daniela Angerame, and Natália Giovanelli Gaspar. "Relato de caso: carcinoma ductal de mama com metástase de endométrio." In 45º Congresso da SGORJ XXIV Trocando Ideias. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/jbg-0368-1416-20211311076.
Повний текст джерелаMishra, Amita, Archit Pandit, Namit Kalra, and Bhawna Narula. "Primary signet ring cell mucinous carcinoma ovary: A very rare neoplasm." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685405.
Повний текст джерелаSoni, Abhishek, Nupur Bansal, A. K. Dhull, Vivek Kaushal, Rajeev Atri, and Monica Verma. "Diagnostic dilemma of mesonephric adenocarcinoma cervix." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685283.
Повний текст джерелаJain, Nidhi, Rahul Manchanda, Anshika Lekhi, Sravani Chithra, and Hena Kausar. "Primary clear cell adenocarcinoma of cervix in a young women: A rare entity." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685279.
Повний текст джерелаJaishuen, A., J. Petsuksiri, P. Karavanich, V. Achariyapota, S. Kuljarusnont, and P. Inthasorn. "EP538 Prediction of pelvic lymph node metastasis in endometrioid endometrial carcinoma." In ESGO Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/ijgc-2019-esgo.596.
Повний текст джерелаKhemworapong, Khemanat, Pattra Wisarnsirirak, Atthapon Jaishuen, Boonlert Viriyapak, Pisutt Srichaikul, Vuthinun Achariyapota, and Nida Jareemit. "Survival benefit of para-aortic lymph node evaluation in endometrioid endometrial carcinoma." In The 7th Biennial Meeting of Asian Society of Gynecologic Oncology. Korea: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology, 2021. http://dx.doi.org/10.3802/jgo.2021.32.s1.e15.
Повний текст джерела